Discussion
HFpEF
The impact of SGLT2i treatment on myocardial energy metabolism in patients with HF remains hotly debated but continues to be poorly understood. EMPA-VISION is the first trial to investigate effects of empagliflozin treatment in patients with HFrEF and HFpEF on cardiac energetics and metabolism. The principal findings of our trial are: (1) after 12 weeks of empagliflozin (10 mg once daily) versus placebo, there was no difference in the primary end point (myocardial energetics in vivo via 